SESSION 12: INDOLENT LYMPHOMAS
INTRATUMORAL T-CELLS HAVE A DIFFERENTIAL IMPACT ON FDG-PET PARAMETERS IN FOLLICULAR LYMPHOMA abstract
K. Nath, Soi-C. Law, D. Talaulikar, M. B. Sabdia, et al.
The study authors conclude that this is the first prospective trial investigating the role of DAAs in HCV+ iNHL patients not requiring immediate conventional treatment. Their results suggest that HCV eradication with DAAs should be considered as first-line therapy in this setting.
DIRECT-ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV-ASSOCIATED INDOLENT NON-HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI abstract
M. Merli, S. Rattotti, M. Spina, F. Re, M. Motta, et al.
The study authors conclude that this is the first prospective trial investigating the role of DAAs in HCV+ iNHL pts not requiring immediate conventional treatment. Their results suggest that HCV eradication with DAAs should be considered as first-line therapy in this setting.
PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31) abstract
A. Conconi, B. Vannata, A. Janikova, A. Ramirez, et al.
The study authors conclude that their findings support the hypothesis that some primary lymphoma localizations may represent specific entities.
PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2-YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38) abstract
M. C. Pirosa, L. Orsucci, P. Feugier, M. Tani, et al.
The study authors show that IELSG38 is the first trial that specifically evaluated subcutaneous rituximab maintenance in patients with MALT lymphoma. They demonstrate Long-term disease control in the majority of patients and, despite the inclusion of more high-risk patients (30% vs. 17%), the 5 year PFS (87% vs. 72%) compared favorably with the IELSG19 trial. There were no new safety signals.
RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL). abstract
S. Luminari, S. Galimberti, A. Versari, A. Tucci, et al.
The study authors conclude that a metabolic and a molecular response adapted therapy as assessed in the FOLL12 study was associated with a significantly inferior progression-free survival compared to 2-year rituximab maintenance. The better efficacy of standard RM was confirmed in the subgroup analysis and in particular for patients achieving both CMR and MRD-.
IMMUNE PRIMING WITH NIVOLUMAB FOLLOWED BY NIVOLUMAB & RITUXIMAB IN 1ST LINE TREATMENT OF FOLLICULAR LYMPHOMA: THE PHASE 2 1ST FLOR STUDY abstract
E. A. Hawkes, S. T. Lee, G. Chong, M. Gilbertson, et al.
The study authors conclude that immune-priming with single-agent nivolumab (N), then combination N+R in 1L FL is associated with favorable toxicity and high ORR & CR rates potentially providing an alternative to chemotherapy.